Femasys advances final FemBloc trial phase with $12M financing

Rhea-AI Filing Summary

Femasys Inc. (FEMY) announced FDA approval to advance the final FemBloc trial phase and a financing of $12 million, with potential to reach $58 million. The company disclosed these developments via a press release furnished as an exhibit. FDA clearance to proceed in the trial process is a key step toward generating pivotal clinical data for FemBloc, while the financing provides added capital to support program execution.

The announcement pairs a regulatory milestone with near-term funding. The $12 million financing, and the stated potential to reach $58 million, signal additional resources that can help sustain clinical progress and operations as the FemBloc program advances.

Insights

Biotech and Capital Markets Analyst

Regulatory step forward paired with new financing capacity.

Femasys reported FDA approval to advance the final FemBloc trial phase alongside a $12 million financing, with potential to reach $58 million. Advancing to a final trial phase is a notable regulatory milestone because it enables collection of data that can inform future regulatory submissions. The financing indicates available capital to support this stage.

The specific financing structure and timing were not detailed in the excerpt, so cash availability may depend on meeting conditions or staged mechanisms. Trial execution, enrollment, and data quality remain critical dependencies common to late-stage programs.

Key items relate to the progress of the final FemBloc trial phase and any subsequent disclosures about financing drawdown mechanics. Subsequent filings may provide specifics on terms and milestones tied to both the trial and funding access.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false0001339005NASDAQ00013390052025-11-032025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

Femasys Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40492		11-3713499
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100 Suwanee, Georgia		30024
(Address of principal executive offices)		(Zip Code)

(770) 500-3910

(Registrant’s telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		FEMY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events

On November 3, 2025, Femasys Inc. (the “Company”) issued a press release announcing that Femasys Secures FDA Approval to Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of Femasys Inc. dated November 3, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Femasys Inc.
	By:	/s/ Kathy Lee-Sepsick
	Names: Kathy Lee-Sepsick
	Title: Chief Executive Officer
Date: November 3, 2025

FAQ

What did Femasys (FEMY) announce?

Femasys announced FDA approval to advance the final FemBloc trial phase and a $12 million financing, with potential to reach $58 million.

How much financing did Femasys (FEMY) secure?

The company disclosed $12 million in financing, with potential to reach $58 million.

What is the regulatory update for FemBloc?

Femasys reported FDA approval to advance the final phase of the FemBloc clinical trial.

Where did Femasys (FEMY) disclose these details?

The company furnished a press release as an exhibit summarizing the FDA trial advancement and financing.

Does the filing describe how the financing will be used?

The excerpt cites the financing amounts but does not detail specific uses.

Is there information on trial timelines or results?

The excerpt notes advancement to the final trial phase but does not provide timelines or results.